Table 2.

Assessment of arteries at week 96 in patients who received tocilizumab^a

Arteries, mean (s.d.) (%)	Improved	Stable			Partially progressed	Newly progressed	Unevaluable
Baseline condition	Abnormal	Total	Abnormal	Normal	Abnormal	Normal	NA
Wall thickness	0.5 (0.9)   (2.1)	18.6 (4.2)   (84.6)	2.9 (2.6)   (13.3)	15.7 (4.3)   (71.3)	0.5 (1.0)   (2.4)	0.8 (1.5)   (3.6)	1.6 (4.1)   (7.3)
Dilatation/aneurysm	0.0   0	21.2 (1.0)   (96.3)	0.6 (1.0)   (2.9)	20.5 (1.4)   (93.3)	0.1 (0.3)   (0.3)	0.1 (0.6)   (0.5)	0.6 (0.8)   (2.9)
Stenosis/occlusion	0.1 (0.4)   (0.6)	20.3 (4.1)   (92.2)	1.0 (1.0)   (4.4)	19.3 (4.0)   (87.8)	0.0   (0.0)	0.2 (0.8)   (1.0)	1.4 (4.1)   (6.2)
Wall enhancement	0.0 (0.2)   (0.2)	19.0 (4.4)   (86.5)	3.4 (2.8)   (15.3)	15.7 (4.1)   (71.3)	0.0   (0.0)	0.6 (1.3)   (2.6)	2.4 (4.3)   (10.7)

Data are shown for all patients with central radiological assessment who received at least one dose of tocilizumab (N = 28). ^aPercentages are based on 22 arteries assessed in each patient. Imaging data were evaluated at 96 weeks (day 673; range, days 505–841). If multiple scans were available during the time window, the scan conducted closest to the scheduled date was used. NA, not applicable.